This Market Spotlight report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

• Datamonitor Healthcare estimates that in 2016, there were 312,000 incident cases of thyroid cancer worldwide, and forecasts that number to increase to 342,000 incident cases by 2025.
• Asia is estimated to have had the largest number of incident cases in 2016 (151,000 cases), while the Oceania region is estimated to have had the smallest number (3,000 cases).
• The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.
• Half of all industry-sponsored drugs in active clinical development for thyroid cancer are in Phase II, with only one drug in Phase III.
• Therapies in the pipeline for thyroid cancer focus on a wide variety of targets. These pipeline drugs are administered via the oral, intravenous, and subcutaneous routes.
• High impact upcoming events for drugs in the thyroid cancer space comprise topline Phase III results for selumetinib and Phase II results for GI-6207 and Cometriq.
• There have been 12 licensing and asset acquisition deals involving thyroid cancer drugs during 2013–18. The $1,119m exclusive licensing agreement in February 2016 between Exelixis and Ipsen for the commercialization and further development of Cometriq was the largest deal.
• The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
• The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major EU markets, while Japan has the top spot in Asia.
• Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for thyroid cancer, with 27 trials.
• Novartis leads industry sponsors with the highest number of clinical trials for thyroid cancer, followed by Pfizer and GlaxoSmithKline.